CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) rose 7.8% during mid-day trading on Friday . The stock traded as high as $0.15 and last traded at $0.14. 1,923,801 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 2,548,531 shares. The stock had previously closed at $0.13.
CytoDyn Price Performance
The firm's 50-day moving average price is $0.13 and its 200 day moving average price is $0.14. The firm has a market capitalization of $168.27 million, a price-to-earnings ratio of -6.90 and a beta of 0.14.
CytoDyn (OTCMKTS:CYDY - Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share for the quarter.
CytoDyn Company Profile
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
